Literature DB >> 12530119

Do the molecules CD26 and lymphocytes activation gene-3 differentiate between type 1 and 2 T cell response?

Barbara Rogala1, Joanna Glück, Bogdan Mazur.   

Abstract

BACKGROUND: The Th1/Th2 paradigm is considered to be responsible for the development of many immunological disorders, including atopic diseases and diabetes mellitus type 1. So far, however, no unequivocal markers identifying the two subpopulations of T cells have been found.
OBJECTIVE: To examine the expression of two putative markers of Th1-mediated disorders, CD26 and lymphocytes activation gene-3 molecules, on CD4+ and CD8+ lymphocytes in the peripheral blood of atopic and diabetic donors.
METHODS: 11 patients (9 males/2 females, age range: 21-29, median age: 23) suffering from episodic atopic bronchial asthma (AO group) and 11 patients (9 males/2 females, age range: 33-47, median age: 42) with insulin-dependent diabetes mellitus (DM group) were included into the study. Atopy was excluded in all diabetic patients. The following T cell subsets were analyzed by flow cytometry (FAC-Scan): CD8+CD26+, CD4+CD26+, CD4+LAG-3+, CD8+LAG-3+, and CD56+. Nonparametric tests were used for statistical analysis, and results were expressed as median and quartile range.
RESULTS: Among all analyzed T cell subsets, the number of CD4+LAG-3+ and CD8+LAG-3+ cells was significantly higher in the A0 group--8.3% (5.4-11.7) vs DM 5.4% (3.9-5.9), p < 0.05, and 13.3% (8.8-19) vs DM: 7.1% (6.2-8.3), p < 0.008, respectively. The ratio between CD4+/CD8+ subsets was similar in both groups: CD4+CD26+/CD8+CD26+--AO: 7.2 (5.3-10.1); DM: 6.4 (5.5-12.6), p = 0.77 and CD4+LAG-3+/CD8+LAG-3+--AO: 0.64 (0.58-0.67); DM: 0.71 (0.64-0.78), p = 0.082.
CONCLUSION: The results suggest that the two examined putative markers of type 1 T cells do not discriminate between Th1- and Th2-dominated responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530119

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  5 in total

Review 1.  LAG-3 in Cancer Immunotherapy.

Authors:  Monica V Goldberg; Charles G Drake
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 2.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

3.  Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.

Authors:  Anne Fröhlich; Judith Sirokay; Simon Fietz; Timo J Vogt; Jörn Dietrich; Romina Zarbl; Mike Florin; Pia Kuster; Gonzalo Saavedra; Susana Ramírez Valladolid; Friederike Hoffmann; Lukas Flatz; Sandra S Ring; Carsten Golletz; Torsten Pietsch; Sebastian Strieth; Peter Brossart; Gerrit H Gielen; Glen Kristiansen; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  EBioMedicine       Date:  2020-08-30       Impact factor: 8.143

4.  CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis.

Authors:  R Jafari-Shakib; S Ajdary; Z Mohtasham Amiri; A M Mohammadi; K Nourijelyani; H Mortazavi; M A Shokrgozar; B Nikbin; A Khamesipour
Journal:  Clin Exp Immunol       Date:  2008-05-05       Impact factor: 4.330

Review 5.  CD26 and Asthma: a Comprehensive Review.

Authors:  Juan J Nieto-Fontarigo; Francisco J González-Barcala; Esther San José; Pilar Arias; Montserrat Nogueira; Francisco J Salgado
Journal:  Clin Rev Allergy Immunol       Date:  2019-04       Impact factor: 8.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.